Living

US FDA staff says data may support effectiveness of Moderna's flu vaccine in older adults

By Reuters Reuters
A U.S. flag, a U.S. Food and Drug Administration (FDA) logo, a syringe and a vial are seen in this illustration taken May 13, 2025. REUTERS/Dado Ruvic/Illustration
A U.S. flag, a U.S. Food and Drug Administration (FDA) logo, a syringe and a vial are seen in this illustration taken May 13, 2025. REUTERS/Dado Ruvic/Illustration Dado Ruvic Reuters

The U.S. Food and Drug Administration's staff reviewers said preliminary assessment of Moderna's flu shot data may support effectiveness in adults 65 years and older.

Moderna's shot mFlusiva showed superior relative vaccine efficacy versus a standard-dose flu vaccine in adults 50 years and older, according to briefing documents published on Tuesday.

(Reporting by Christy Santhosh in Bengaluru; Editing by Shilpi Majumdar)

Copyright Reuters or USA Today Network via Reuters Connect

This story was originally published June 16, 2026 at 9:12 AM.

Get unlimited digital access
#ReadLocal

Try 1 month for $1

CLAIM OFFER